Fortress Biotech Past Earnings Performance
Past criteria checks 0/6
Fortress Biotech's earnings have been declining at an average annual rate of -13%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 31.6% per year.
Key information
-13.0%
Earnings growth rate
7.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 31.6% |
| Return on equity | n/a |
| Net Margin | -126.4% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Fortress Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 62 | -78 | 100 | 0 |
| 30 Jun 23 | 63 | -96 | 108 | 0 |
| 31 Mar 23 | 64 | -92 | 113 | 0 |
| 31 Dec 22 | 76 | -87 | 114 | 0 |
| 30 Sep 22 | 78 | -97 | 113 | 0 |
| 30 Jun 22 | 82 | -93 | 105 | 0 |
| 31 Mar 22 | 81 | -74 | 96 | 0 |
| 31 Dec 21 | 69 | -65 | 87 | 0 |
| 30 Sep 21 | 64 | -38 | 75 | 0 |
| 30 Jun 21 | 53 | -33 | 68 | 0 |
| 31 Mar 21 | 44 | -43 | 63 | 0 |
| 31 Dec 20 | 46 | -47 | 61 | 0 |
| 30 Sep 20 | 43 | -57 | 60 | 24 |
| 30 Jun 20 | 43 | -54 | 59 | 39 |
| 31 Mar 20 | 43 | -54 | 58 | 58 |
| 31 Dec 19 | 37 | -40 | 56 | 81 |
| 30 Sep 19 | 34 | -45 | 56 | 83 |
| 30 Jun 19 | 30 | -51 | 54 | 87 |
| 31 Mar 19 | 27 | -53 | 53 | 86 |
| 31 Dec 18 | 27 | -73 | 53 | 87 |
| 30 Sep 18 | -107 | -61 | 38 | 77 |
| 30 Jun 18 | -65 | -69 | 45 | 73 |
| 31 Mar 18 | -22 | -72 | 48 | 69 |
| 31 Dec 17 | 17 | -65 | 49 | 52 |
| 30 Sep 17 | 155 | -74 | 57 | 49 |
| 30 Jun 17 | 109 | -60 | 47 | 41 |
| 31 Mar 17 | 61 | -55 | 39 | 36 |
| 31 Dec 16 | 16 | -55 | 33 | 35 |
| 30 Sep 16 | 4 | -50 | 32 | 30 |
| 30 Jun 16 | 3 | -55 | 30 | 33 |
| 31 Mar 16 | 1 | -49 | 26 | 29 |
| 31 Dec 15 | 1 | -48 | 22 | 30 |
| 30 Sep 15 | 1 | -40 | 18 | 25 |
| 30 Jun 15 | 1 | -27 | 13 | 16 |
| 31 Mar 15 | 1 | -25 | 12 | 15 |
| 31 Dec 14 | 0 | -20 | 10 | 10 |
| 30 Sep 14 | 0 | -26 | 10 | 14 |
| 30 Jun 14 | 0 | -30 | 10 | 17 |
| 31 Mar 14 | 0 | -36 | 10 | 22 |
| 31 Dec 13 | 0 | -37 | 10 | 26 |
| 30 Sep 13 | 0 | -36 | 10 | 24 |
| 30 Jun 13 | 0 | -34 | 10 | 22 |
Quality Earnings: CNB1 is currently unprofitable.
Growing Profit Margin: CNB1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNB1 is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare CNB1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNB1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: CNB1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.